Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Rinsho Ketsueki ; 62(11): 1593-1597, 2021.
Article in Japanese | MEDLINE | ID: mdl-34866081

ABSTRACT

Chronic myeloid leukemia (CML) is a clonal hemopoietic stem cell disorder characterized by reciprocal translocation between the long arms of chromosomes 9 and 22 that produces the fusion BCR-ABL1 gene. Major manifestations in CML patients are increased white cell count and splenomegaly. In this case, the patient presented with aseptic meningitis and showed symptoms, such as disorientation, double vision, and neurogenic bladder disorder. Pulse steroid and antibiotic treatment was ineffective for these symptoms; however, the combination therapy with these drugs and dasatinib was very effective. Moreover, our patient had myelopathy that could have been induced by dasatinib after the treatment was started. To our knowledge, this is the first report of meningitis of the paraneoplastic syndrome associated with CML.


Subject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Meningitis, Aseptic , Paraneoplastic Syndromes , Dasatinib/therapeutic use , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Translocation, Genetic
2.
Acta Med Okayama ; 71(4): 341-344, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28824190

ABSTRACT

We report a case of a woman with typical dermatomyositis (DM) with skin manifestations, severe myalgia and muscle weakness complicated by interstitial lung disease (ILD) and pneumomediastinum. Pneumomediastinum persisted despite treatment with immunosuppressive therapy (steroids and cyclosporine). After the test for anti-melanoma differentiation-associated gene 5 (MDA5) antibody came out positive, we doubled the cyclosporine dose and her condition improved. Despite typical clinical features of DM, in cases complicated by pneumomediastinum or steroid resistance, measurement of anti-MDA5 antibody may be useful for immunosuppressant dose titration.


Subject(s)
Antibodies/blood , Dermatomyositis/genetics , Dermatomyositis/immunology , Interferon-Induced Helicase, IFIH1/immunology , Aged , Cyclosporine/administration & dosage , Cyclosporine/therapeutic use , Dermatomyositis/blood , Dermatomyositis/drug therapy , Female , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/therapeutic use
4.
Neurol Res ; 33(4): 427-32, 2011 May.
Article in English | MEDLINE | ID: mdl-21535943

ABSTRACT

OBJECTIVE: To investigate whether acoustic impairment can be one of the characteristic extracerebellar symptoms in sporadic and hereditary ataxias including spinocerebellar ataxia type 31 (SCA31). METHODS: We investigated genotypes of dominant ataxia families, and determined a frequency of each form in our cohort of 154 families. Acoustic function in the groups of various forms of ataxia with multiple system atrophy of cerebellar predominance (MSA-C), cortical cerebellar atrophy (CCA), and hereditary ataxias including SCA31 was evaluated by using audiogram and brainstem auditory evoked potentials (BAEPs). RESULTS: Genetic analysis of dominant ataxia families revealed that a frequency of SCA31 in our cohort was fewer than that reported from other areas of Japan, indicating that SCA31 is not widely distributed throughout Japan. Results of audiogram showed no significant difference of hearing levels among ataxic groups, and those of BAEPs did not support inner ear dysfunction in SCA31 in which hearing loss had initially been suggested as one of its characteristic symptoms. CONCLUSION: This study suggests that acoustic impairment is neither specific to SCA31, MSA-C and CCA nor useful in making a differential diagnosis among them.


Subject(s)
Hearing Disorders/epidemiology , Hearing Disorders/genetics , Spinocerebellar Ataxias/epidemiology , Spinocerebellar Ataxias/genetics , Adult , Aged , Atrophy , Cerebellum/abnormalities , Cerebellum/pathology , Cohort Studies , Comorbidity , Diagnosis, Differential , Female , Genes, Dominant/physiology , Genetic Predisposition to Disease/genetics , Hearing Disorders/pathology , Humans , Male , Middle Aged , Pedigree , Prevalence , Spinocerebellar Ataxias/pathology , Spinocerebellar Degenerations/epidemiology , Spinocerebellar Degenerations/genetics , Spinocerebellar Degenerations/pathology
5.
Cell Transplant ; 20(1): 95-7, 2011.
Article in English | MEDLINE | ID: mdl-20887680

ABSTRACT

Possible strategies for treating stroke include: 1) thrombolytic therapy with tissue plasminogen activator (tPA): restoring cerebral blood flow in the acute phase of ischemic stroke but sometimes causing hemorrhagic transformation (HT); 2) stem cell therapy: the repair of disrupted neuronal networks with newly born neurons in the chronic phase of ischemic stroke. Firstly, we estimated the vascular protective effect of a free radical scavenger, edaravone, in the tPA-treated rat model of middle cerebral artery occlusion. Edaravone prevented dramatically decreased the hemorrhagic transformation and improved the neurologic score and survival rate of tPA-treated rats. Secondly, we attempted to restore brain tissue using a novel biomaterial, polydimethysiloxane-tetraethoxysilane (PDMS-TEOS) hybrid with or without vascular endothelial growth factor (VEGF), and we could show that implantation of a PDMS-TEOS scaffold with VEGF might be effective for treating old brain infarction or trauma. In the future, we will combine these strategies to develop more effective therapies for treatment of strokes.


Subject(s)
Brain Ischemia/therapy , Endothelium, Vascular/physiology , Stroke/therapy , Animals , Brain Ischemia/complications , Brain Ischemia/pathology , Dimethylpolysiloxanes/chemistry , Dimethylpolysiloxanes/therapeutic use , Neural Stem Cells/cytology , Neural Stem Cells/transplantation , Rats , Silanes/chemistry , Silanes/therapeutic use , Stroke/etiology , Stroke/pathology , Tissue Plasminogen Activator/therapeutic use , Vascular Endothelial Growth Factor A/therapeutic use
6.
J Cereb Blood Flow Metab ; 30(8): 1487-93, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20216552

ABSTRACT

Stroke is a major neurologic disorder. Induced pluripotent stem (iPS) cells can be produced from basically any part of patients, with high reproduction ability and pluripotency to differentiate into various types of cells, suggesting that iPS cells can provide a hopeful therapy for cell transplantation. However, transplantation of iPS cells into ischemic brain has not been reported. In this study, we showed that the iPS cells fate in a mouse model of transient middle cerebral artery occlusion (MCAO). Undifferentiated iPS cells (5 x 10(5)) were transplanted into ipsilateral striatum and cortex at 24 h after 30 mins of transient MCAO. Behavioral and histologic analyses were performed at 28 day after the cell transplantation. To our surprise, the transplanted iPS cells expanded and formed much larger tumors in mice postischemic brain than in sham-operated brain. The clinical recovery of the MCAO+iPS group was delayed as compared with the MCAO+PBS (phosphate-buffered saline) group. iPS cells formed tridermal teratoma, but could supply a great number of Dcx-positive neuroblasts and a few mature neurons in the ischemic lesion. iPS cells have a promising potential to provide neural cells after ischemic brain injury, if tumorigenesis is properly controlled.


Subject(s)
Brain/pathology , Induced Pluripotent Stem Cells/transplantation , Infarction, Middle Cerebral Artery/surgery , Animals , Brain/cytology , Brain/surgery , Brain Ischemia/pathology , Brain Ischemia/surgery , Brain Ischemia/therapy , Cell Survival , Doublecortin Protein , Induced Pluripotent Stem Cells/cytology , Induced Pluripotent Stem Cells/pathology , Infarction, Middle Cerebral Artery/pathology , Infarction, Middle Cerebral Artery/therapy , Male , Mice , Mice, Inbred C57BL , Motor Activity , Neoplastic Processes , Neurogenesis
7.
Cell Transplant ; 18(9): 999-1002, 2009.
Article in English | MEDLINE | ID: mdl-19523331

ABSTRACT

Possible strategies for treating ischemic stroke include neuroprotection (preventing injured neurons from undergoing apoptosis in the acute phase of cerebral ischemia) and stem cell therapy (the repair of disrupted neuronal networks with newly born neurons in the chronic phase of cerebral ischemia). First, we estimated the neuroprotective effect of glial cell line-derived neurotrophic factor (GDNF) by administration of GFNF protein. GDNF protein showed a direct protective effect against ischemic brain damage. Pretreatment of animals with adenoviral vector containing GDNF gene (Ad-GDNF) 24 h before the subsequent transient middle cerebral artery occlusion (MCAO) effectively reduced infarcted volume. Secondly, we studied the neuroprotective effect of a calcium channel blocker, azelnidipine, or a by-product of heme degradation, biliverdin. Both azelnidipine and biliverdin had a neuroprotective effect in the ischemic brain through their antioxidative property. Lastly, we developed a restorative stroke therapy with a bioaffinitive scaffold, which is able to provide an appropriate platform for newly born neurons. In the future, we will combine these strategies to develop more effective therapies for treatment of strokes.


Subject(s)
Brain Ischemia/drug therapy , Brain Ischemia/therapy , Genetic Therapy , Stem Cell Transplantation/methods , Animals , Antioxidants/therapeutic use , Azetidinecarboxylic Acid/analogs & derivatives , Azetidinecarboxylic Acid/therapeutic use , Biliverdine/therapeutic use , Dihydropyridines/therapeutic use , Disease Models, Animal , Glial Cell Line-Derived Neurotrophic Factor/genetics , Glial Cell Line-Derived Neurotrophic Factor/physiology , Humans , Models, Biological , Neuroprotective Agents/therapeutic use
8.
Neurol Res ; 30(7): 731-9, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18593521

ABSTRACT

The therapeutic effect of a novel RNA viral vector, Sendai virus (SeV)-mediated glial cell line-derived neurotrophic factor (GDNF) gene (SeV/GDNF), on the infarct volume, was investigated after 90 minutes of transient middle cerebral artery occlusion (tMCAO) in rats with relation to nuclear translocation of apoptosis inducing factor (AIF). The topical administration of SeV/GDNF induced high level expression of GDNF protein, which effectively reduced the infarct volume when administrated 0 and 1 hours as well after the reperfusion. Twenty-four hours after ischemia, the obvious nuclear translocation of AIF was found in neurons of peri-infarct area, which significantly reduced with administration of SeV/GDNF 0 or 1 hour after reperfusion, as well as the number of TUNEL positive cells. These results demonstrate that SeV vector-mediated gene transfer of GDNF effectively reduced ischemic infarct volume after tMCAO and extended the therapeutic time window compared with previous viral vectors, and that promoting neuronal survival of GDNF might be related to the reduction of AIF nuclear translocation, indicating the high therapeutic potency of SeV/GDNF for cerebral ischemia.


Subject(s)
Apoptosis Inducing Factor/metabolism , Gene Transfer Techniques , Genetic Therapy/methods , Glial Cell Line-Derived Neurotrophic Factor/genetics , Hypoxia-Ischemia, Brain/therapy , Sendai virus/genetics , Active Transport, Cell Nucleus/genetics , Animals , Apoptosis/genetics , Apoptosis Inducing Factor/genetics , Brain Infarction/genetics , Brain Infarction/metabolism , Brain Infarction/therapy , Disease Models, Animal , Genetic Vectors/genetics , Glial Cell Line-Derived Neurotrophic Factor/metabolism , Hypoxia-Ischemia, Brain/genetics , Hypoxia-Ischemia, Brain/metabolism , In Situ Nick-End Labeling , Infarction, Middle Cerebral Artery/genetics , Infarction, Middle Cerebral Artery/metabolism , Infarction, Middle Cerebral Artery/therapy , Male , Nerve Degeneration/genetics , Nerve Degeneration/prevention & control , Nerve Degeneration/therapy , Rats , Rats, Wistar , Time Factors , Treatment Outcome , Up-Regulation/genetics
9.
Brain Res ; 1188: 1-8, 2008 Jan 10.
Article in English | MEDLINE | ID: mdl-18035335

ABSTRACT

Biliverdin (BV), one of the byproducts of heme catalysis through heme oxygenase (HO) system, is a scavenger of reactive oxygen species (ROS). We hypothesized that BV treatment could protect rat brain cells from oxidative injuries via its anti-oxidant efficacies. Cerebral infarction was induced by transient middle cerebral artery occlusion (tMCAO) for 90 min, followed by reperfusion. BV or vehicle was administered intraperitoneally immediately after reperfusion. The size of the cerebral infarction 2 days after tMCAO was evaluated by 2,3,5-triphenyltetrazolium chloride (TTC) stain. Superoxide generation 4 h after tMCAO was determined by detection of oxidized hydroethidine. In addition, the oxidative impairment of neurons were immunohistochemically assessed by stain for lipid peroxidation with 4-hydroxy-2-nonenal (4-HNE) and damaged DNA with 8-hydroxy-2'-deoxyguanosine (8-OHdG). BV treatment significantly reduced infarct volume of the cerebral cortices associated with less superoxide production and decreased oxidative injuries of brain cells. The present study demonstrated that treatment with BV ameliorated the oxidative injuries on neurons and decreased brain infarct size in rat tMCAO model.


Subject(s)
Antioxidants/pharmacology , Biliverdine/pharmacology , Cerebral Infarction/drug therapy , Oxidative Stress/drug effects , Aldehydes/metabolism , Animals , Antioxidants/metabolism , Biliverdine/metabolism , Cerebral Infarction/metabolism , Cerebral Infarction/physiopathology , DNA Damage/drug effects , DNA Damage/physiology , Disease Models, Animal , Infarction, Middle Cerebral Artery/drug therapy , Infarction, Middle Cerebral Artery/metabolism , Infarction, Middle Cerebral Artery/physiopathology , Injections, Intraperitoneal , Male , Neurons/drug effects , Neurons/metabolism , Neuroprotective Agents/metabolism , Neuroprotective Agents/pharmacology , Oxidative Stress/physiology , Phenanthridines , Rats , Rats, Wistar , Superoxides/metabolism , Tetrazolium Salts , Treatment Outcome
10.
Curr Neurovasc Res ; 4(4): 268-73, 2007 Nov.
Article in English | MEDLINE | ID: mdl-18045152

ABSTRACT

Statin reduces cerebrovascular events independent of its cholesterol lowering effect. We hypothesized that statin inhibits early atherosclerotic change in common carotid artery (CCA), and investigated its effect on lectin-like oxidized-LDL receptor-1 (LOX-1) and monocyte chemoattractant protein-1 (MCP-1) expression, both of which are early atherosclerotic markers. Stroke-prone spontaneous hypertensive rats (SHR-SP) of 8 weeks old were orally treated with vehicle or simvastatin (20mg/kg) daily. After 4 weeks of simvastatin or vehicle treatment, or 2 weeks of vehicle and 2 weeks of simvastatin treatment, CCA was removed. LOX-1 and MCP-1 expression as well as macrophage infiltration were histologically investigated. Lipid deposition was also investigated by Sudan III staining. Simvastatin groups showed significantly smaller amount of lipid deposition and LOX-1 and MCP-1 expression, independent of serum lipid levels. Macrophage infiltration was also decreased. Reduction of cerebrovascular events by statins may be brought by the direct inhibition of atherosclerotic change.


Subject(s)
Chemokine CCL2/metabolism , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Macrophages/drug effects , Animals , Atherosclerosis/pathology , Atherosclerosis/prevention & control , Carotid Artery, Common/metabolism , Cholesterol/blood , Cholesterol, Dietary/pharmacology , Depression, Chemical , Diet , Dietary Fats/pharmacology , Immunohistochemistry , Leukocyte Count , Lipids , Male , Rats , Rats, Inbred SHR , Simvastatin/pharmacology , Triglycerides/blood
11.
Intern Med ; 46(11): 751-5, 2007.
Article in English | MEDLINE | ID: mdl-17541229

ABSTRACT

We report two patients with spinocerebellar ataxia (SCA) with cranial and spinal motor neuron involvement. They initially presented with cerebellar ataxia, followed by bulbar palsy and limb motor neuron sign. One of the patients had a brother with allied disorder. SCA type 1 (SCA1), SCA3 and SCA6 have been reported to involve the motor neuron system, but they were excluded by DNA analyses in the present two patients. These two patients may form a distinct disease entity among SCAs.


Subject(s)
Bulbar Palsy, Progressive/complications , Motor Neuron Disease/complications , Spinocerebellar Ataxias/complications , Bulbar Palsy, Progressive/diagnosis , DNA/genetics , Electromyography , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Motor Neuron Disease/diagnosis , Muscular Atrophy/complications , Muscular Atrophy/diagnosis , Muscular Atrophy/pathology , Pedigree , Spinocerebellar Ataxias/diagnosis , Spinocerebellar Ataxias/genetics , Tongue/pathology
12.
Brain Res ; 1093(1): 190-7, 2006 Jun 06.
Article in English | MEDLINE | ID: mdl-16701577

ABSTRACT

Nitric oxide (NO) can be neuroprotective or neurotoxic during cerebral ischemia, depending on the NO synthase (NOS) isoform involved. In addition to neurotoxic effect in ischemic brain, inducible NOS (iNOS) also adversely affect ischemic outcome by blocking neurogenesis. In the present study, therefore, we studied the chronological and spatial change of the distribution of iNOS and cell proliferation in subventricular zone (SVZ) after transient focal cerebral ischemia. After 90 min of transient middle cerebral artery occlusion (tMCAO), iNOS-positive cells decreased in the ischemic core at 1 to 21 days, and increased in the ipsilateral periischemic area at 1 and 3 days. 5-Bromodeoxyuridine (BrdU)-positive cells appeared in the ischemic core at 3 to 21 days, appeared in the periischemic area at 3 and 7 days, and increased in the ipsilateral SVZ at 7 days. ED-1-positive cells appeared in the ischemic core at 3 to 21 days, and some of them were double positive with BrdU or iNOS, but the majority were BrdU-negative. The present study suggests that astrocytes are born within the periischemic area at early stage after tMCAO and migrate from SVZ into periischemic area at later stage, and that time-dependent and spatial changes of iNOS expression may be involved in the proliferation and differentiation of adult neurogenesis after focal cerebral ischemia.


Subject(s)
Brain/enzymology , Cell Proliferation , Infarction, Middle Cerebral Artery/enzymology , Nerve Regeneration/physiology , Nitric Oxide Synthase Type II/metabolism , Animals , Brain/pathology , Immunohistochemistry , Male , Neurons/enzymology , Rats , Rats, Wistar , Time Factors
13.
Curr Neurovasc Res ; 3(2): 119-29, 2006 May.
Article in English | MEDLINE | ID: mdl-16719795

ABSTRACT

Angiogenesis occurs in a wide range of conditions. As ischemic tissue usually depends on collateral blood flow from newly produced vessels, acceleration of angiogenesis should be of therapeutic value to ischemic disorders. Indeed, therapeutic angiogenesis reduced tissue injury in myocardial or limb ischemia. In ischemic stroke, on the other hand, angiogenic factors often increase vascular permeability and thus may deteriorate tissue damage. In order to apply safely the therapeutic angiogenesis for ischemic stroke treatment, elucidating precise mechanism of brain angiogenesis is mandatory. In the present article, we review previous reports which investigated molecular mechanisms of angiogenesis. Endothelial cell mitogens, enzymes that degrade surrounding extracellular matrix, and molecules implicated in endothelial cells migration are induced rapidly in the ischemic brain. Their possible neuroprotective or injury exacerbating effects are discussed. Because therapeutic potential of angiogenic factors application had gained much attention, we here extensively reviewed relevant previous reports. In the future however, there is a need to consider angiogenesis in relation with regenerative medicine, as angiogenic factors sometimes possess neuron producing property.


Subject(s)
Brain Ischemia/therapy , Endothelial Cells/metabolism , Neovascularization, Physiologic/physiology , Regeneration/physiology , Stroke/therapy , Angiogenic Proteins/metabolism , Angiogenic Proteins/pharmacology , Angiogenic Proteins/therapeutic use , Animals , Brain Ischemia/physiopathology , Cell Differentiation/drug effects , Cell Differentiation/physiology , Cell Movement/drug effects , Cell Movement/physiology , Endothelial Cells/drug effects , Extracellular Matrix Proteins/drug effects , Extracellular Matrix Proteins/metabolism , Humans , Mitogens/metabolism , Mitogens/pharmacology , Mitogens/therapeutic use , Neovascularization, Physiologic/drug effects , Regeneration/drug effects , Stroke/physiopathology
14.
J Cereb Blood Flow Metab ; 26(10): 1263-73, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16407853

ABSTRACT

For brain tissue regeneration, any scaffold for migrated or transplanted stem cells with supportive angiogenesis is important once necrotic brain tissue has formed a cavity after injury such as cerebral ischemia. In this study, a new porous gelatin-siloxane hybrid derived from the integration of gelatin and 3-(glycidoxypropyl) trimethoxysilane was implanted as a three-dimensional scaffold into a defect of the cerebral cortex. The porous hybrid implanted into the lesion remained at the same site for 60 days, kept integrity of the brain shape, and attached well to the surrounding brain tissues. Marginal cavities of the scaffolds were occupied by newly formed tissue in the brain, where newly produced vascular endothelial, astroglial, and microglial cells were found with bromodeoxyuridine double positivity, and the numbers of those cells were dose-dependently increased with the addition of basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF). Extension of dendrites was also found from the surrounding cerebral cortex to the newly formed tissue, especially with the addition of bFGF and EGF. The present study showed that a new porous gelatin-siloxane hybrid had biocompatibility after implantation into a lesion of the central nervous system, and thus provided a potential scaffold for cell migration, angiogenesis and dendrite elongation with dose-dependent effects of additive bFGF and EGF.


Subject(s)
Brain/physiology , Gelatin/administration & dosage , Implants, Experimental , Regeneration/physiology , Regenerative Medicine/methods , Siloxanes/administration & dosage , Tissue Engineering/methods , Animals , Brain/drug effects , Bromodeoxyuridine , Cell Movement/drug effects , Epidermal Growth Factor/pharmacology , Fibroblast Growth Factor 2/pharmacology , Immunohistochemistry , Male , Phenotype , Porosity , Rats , Rats, Wistar , Regeneration/drug effects
15.
Neurol Res ; 28(8): 822-5, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17288738

ABSTRACT

OBJECTIVES: Reduction of brain plasticity underlies the poor outcome of aged stroke patients. The molecular mechanism of plasticity reduction by aging is uncertain, but disturbed lipid metabolism may be implicated. METHODS: We investigated the expression of low density lipoprotein receptors (LDL-R) and apolipoprotein E (ApoE), both of which play active roles in lipid metabolism in young adult and old rat brains after ischemia. RESULTS: LDL-R, trivially expressed in the sham-operated brain neurons, was increased from day 1 and became prominent at days 7 and 21 at the peri-ischemic cortex. The magnitude was smaller in the old than in the young adult rats. ApoE was increased in the astrocytes and neurons of the peri-ischemic cortex at day 1, which became further pronounced in the neurons but not in the astrocytes at days 7 and 21. ApoE expression was again less prominent in the old animals at days 7 and 21. DISCUSSION: As ApoE-containing lipoprotein is recruited via LDL-R, the present results suggest that old brains had less capability to induce LDL-R, which resulted in impaired recruitment of lipoprotein after the ischemic injury. Impaired lipid recruitment causes disturbance of synaptogenesis and thus brain plasticity reduction. This molecular mechanism may result in poor functional recovery of aged stroke patients.


Subject(s)
Apolipoproteins E/metabolism , Brain Ischemia/metabolism , Gene Expression Regulation/physiology , Receptors, LDL/metabolism , Age Factors , Animals , Brain Ischemia/pathology , Cell Count/methods , Cerebral Cortex/pathology , Immunohistochemistry/methods , Male , Neurons/metabolism , Rats , Time Factors
16.
Brain Res ; 1048(1-2): 59-68, 2005 Jun 28.
Article in English | MEDLINE | ID: mdl-15921666

ABSTRACT

The endoplasmic reticulum (ER) plays an important role in ischemic neuronal cell death. In order to determine the effect of dantrolene, a ryanodine receptor antagonist, on ER stress response and ischemic brain injury, we investigated changes in ER stress-related molecules, that is phosphorylated form of double-stranded RNA-activated protein kinase (PKR)-like ER kinase (p-PERK), phosphorylated form of eukaryotic initiation factor 2alpha (p-eIF2alpha), activating transcription factor-4 (ATF-4), and C/EBP-homologous protein (CHOP), as well as terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) in the peri-ischemic area and ischemic core region of rat brain after transient middle cerebral artery occlusion (MCAO). In contrast to the cases treated with vehicle, the infarct volume and TUNEL-positive cells were significantly reduced at 24 h of reperfusion by treatment with dantrolene. The immunoreactivities for p-PERK, p-eIF2alpha, ATF-4, and CHOP were increased at the ischemic peripheral region after MCAO, which were partially inhibited by dantrolene treatment. The present results suggest that dantrolene significantly decreased infarct volume and provided neuroprotective effect on rats after transient MCAO by reducing ER stress-mediated apoptotic signal pathway activation in the ischemic area.


Subject(s)
Dantrolene/therapeutic use , Endoplasmic Reticulum/metabolism , Gene Expression Regulation/drug effects , Ischemia/prevention & control , Muscle Relaxants, Central/therapeutic use , Neurons/drug effects , Activating Transcription Factor 4 , Analysis of Variance , Animals , Blotting, Western/methods , CCAAT-Enhancer-Binding Proteins/metabolism , Cell Count/methods , Cell Death/drug effects , Disease Models, Animal , Endoplasmic Reticulum/drug effects , Eukaryotic Initiation Factor-2/metabolism , Glial Fibrillary Acidic Protein/metabolism , Immunohistochemistry/methods , In Situ Nick-End Labeling/methods , Infarction, Middle Cerebral Artery/complications , Ischemia/etiology , Ischemia/pathology , Male , Phosphopyruvate Hydratase/metabolism , Phosphorylation , Rats , Rats, Wistar , Reperfusion/methods , Time Factors , Transcription Factor CHOP , Transcription Factors/metabolism , eIF-2 Kinase/metabolism
17.
Brain Res ; 1037(1-2): 52-8, 2005 Mar 10.
Article in English | MEDLINE | ID: mdl-15777752

ABSTRACT

Statins possess neuroprotective effect against ischemic damage, but how they protect neurons is not exactly made clear. We speculated that anti-oxidative property of statins is implicated, and investigated statins' influences on the oxidative neuronal damage in the brain after ischemia. After 14 days of atorvastatin, pitavastatin, simvastatin, or vehicle administration, 90 min of middle cerebral artery occlusion was imposed on Wistar rats. The production of 4-hydroxynonenal (HNE) and 8-hydroxy-2'-deoxyguanosine (8-OHdG), both of which are oxidative stress markers, as well as infarction formation were investigated at 1 day after the reperfusion. In the vehicle group, massive infarction was confirmed and HNE and 8-OHdG are robustly produced. In the statins-treated group, the infarction was smaller and the HNE and 8-OHdG production was less prominent than the vehicle group. Among the statins investigated, simvastatin was most effective for reducing oxidative stress and infarction volume, which may be brought by its highly lipophilic property. Reduction of oxidative stress by statins may be one main reason in ameliorating ischemic brain damage in rats.


Subject(s)
Brain Ischemia/pathology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Neurons/pathology , Oxidative Stress/drug effects , Aldehydes/metabolism , Animals , Biomarkers , Brain/pathology , Brain Chemistry/drug effects , Brain Chemistry/physiology , Cholesterol/blood , Cholesterol/metabolism , Immunohistochemistry , Infarction, Middle Cerebral Artery/pathology , Lipid Peroxidation/drug effects , Male , Neurons/drug effects , Rats , Rats, Wistar , Triglycerides/blood , Triglycerides/metabolism
18.
Brain Res ; 1037(1-2): 194-9, 2005 Mar 10.
Article in English | MEDLINE | ID: mdl-15777769

ABSTRACT

Neurocan is one of the major chondroitin sulfate proteoglycans in the nervous tissues. The expression and proteolytic cleavage of neurocan are developmentally regulated in the normal rat brain, and the full-length neurocan is detected in juvenile brains but not in normal adult brains. Recently, some studies showed that the full-length neurocan was detectable even in the adult brain when it was exposed to mechanical incision or epileptic stimulation. In the present study, we demonstrated by Western blot analysis that the full-length neurocan transiently appeared in the peri-ischemic region of transient middle cerebral artery occlusion (tMCAO) in adult rat with a peak level at 4 days after tMCAO. Immunohistochemical analysis showed that a clear positive signal of neurocan was observed 4 days after tMCAO in the peri-ischemic region of cerebral cortex and caudate, where cells strongly positive in GFAP expression were also distributed. These results indicate that accumulation of the full-length neurocan produced by reactive astrocytes may be one of the processes for tissue repair and reconstruction of neural networks after focal brain ischemia as well.


Subject(s)
Chondroitin Sulfate Proteoglycans/biosynthesis , Infarction, Middle Cerebral Artery/metabolism , Nerve Tissue Proteins/biosynthesis , Animals , Astrocytes/metabolism , Blotting, Western , Brain Chemistry , Chondroitin Sulfates/metabolism , Glial Fibrillary Acidic Protein/metabolism , Immunohistochemistry , Lectins, C-Type , Male , Myocardial Reperfusion Injury/metabolism , Neurocan , Rats , Rats, Wistar
19.
Brain Res ; 1038(1): 41-9, 2005 Mar 15.
Article in English | MEDLINE | ID: mdl-15748871

ABSTRACT

Ischemia/hypoxia (I/H) causes severe perinatal brain disorders such as cerebral palsy. The neonatal brain possesses much plasticity, and to enhance new cell production would be an innovative means of therapy for such disorders. In order to elucidate the dynamic changes of neural progenitor cells in the neonatal brain after ischemia, we investigated new cells production in the subventricular zone and subsequent migration of these cells to the injured area. Newly produced cells were confirmed by incorporation of bromodeoxyuridine (BrdU), and attempt for differentiation was investigated by immunohistochemistry for molecular markers of each cellular lineage. In the sham-control brain, there were many BrdU-labeled cells which gradually decreased as the animal becomes older. Many of these cells were oligodendroglial progenitor or microglial cells. Although there were only few neuronal cells labeled for BrdU in the sham-control, they dramatically increased after I/H. They were located at just beneath the subventricular zone where the progenitor cells reside and to the injured area, indicating that newly produced cells migrated to the infarct region and differentiated into neuronal precursor cells in order to compensate the lost neural cells. We found that BrdU-labeled astroglial, oligodendroglial progenitor, and microglial cells were also increased after I/H, suggesting that they also play active roles in recovery. Progenitor cells may have potential for treating perinatal brain disorders.


Subject(s)
Brain/metabolism , Cell Division/physiology , Cell Movement/physiology , Hypoxia-Ischemia, Brain/metabolism , Hypoxia-Ischemia, Brain/pathology , Lateral Ventricles/metabolism , Animals , Animals, Newborn , Brain/cytology , Disease Models, Animal , Immunohistochemistry , Lateral Ventricles/cytology , Neuroglia/cytology , Neuroglia/metabolism , Neurons/cytology , Neurons/metabolism , Rats , Rats, Wistar , Recovery of Function/physiology , Stem Cells/cytology , Stem Cells/metabolism
20.
Stroke ; 36(3): 670-2, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15692108

ABSTRACT

BACKGROUND AND PURPOSE: This study aimed to clarify the effect of statins on spontaneous stroke and to examine the antioxidative effect in artificial transient middle cerebral artery occlusion (tMCAO). METHODS: Stroke-prone spontaneous hypertensive rats (SHR-SP) were treated with pitavastatin, atorvastatin, simvastatin, or vehicle for 4 weeks. Physiological parameters, serum lipids, and infarct volumes were examined. The markers for oxidative stresses on lipids and DNA were immunohistochemically detected in vehicle-treated or simvastatin-treated SHR-SP with tMCAO. RESULTS: Atorvastatin and simvastatin decreased infarct volumes, with simvastatin most effective. Simvastatin significantly reduced immunoreactivities for oxidative stress markers for lipids and DNA in neurons after tMCAO. CONCLUSIONS: The results suggest that the antioxidative properties of statins may be implicated in their beneficial effects against neuronal damage in cerebral ischemia.


Subject(s)
Hydroxymethylglutaryl CoA Reductases/therapeutic use , Infarction, Middle Cerebral Artery/prevention & control , Oxidative Stress/physiology , 8-Hydroxy-2'-Deoxyguanosine , Aldehydes/immunology , Animals , Atorvastatin , Blood Pressure/physiology , Body Weight/physiology , Deoxyguanosine/analogs & derivatives , Deoxyguanosine/immunology , Disease Models, Animal , Heptanoic Acids/therapeutic use , Infarction, Middle Cerebral Artery/blood , Infarction, Middle Cerebral Artery/metabolism , Infarction, Middle Cerebral Artery/pathology , Lipids/blood , Lysine/immunology , Pyrroles/therapeutic use , Quinolines/therapeutic use , Rats , Rats, Inbred SHR , Simvastatin/therapeutic use , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...